On December 11, 2025, Cadrenal Therapeutics, Inc. (CVKD) acquired VLX-1005 and related assets for Heparin-Induced Thrombocytopenia (HIT) treatment. The 8-K filing disclosed a $200,000 closing payment for the asset purchase from Veralox Therapeutics, Inc., executed on December 10, 2025.

VLX-1005, a Phase 2 candidate for HIT, received both Orphan Drug and Fast Track Designations from the FDA. According to the filing, preclinical data showed the drug demonstrated dose-dependent prevention of platelet aggregation without increasing bleeding in murine models. The asset also inhibited thrombus formation and pulmonary embolism while preserving normal hemostasis.

Cadrenal Therapeutics, led by CEO and Founder Quang X. Pham, maintains a pipeline including tecarfarin for end-stage kidney disease patients with atrial fibrillation and LVAD patients, and frunexian for complex cardiac surgery and continuous renal replacement therapy patients. Both tecarfarin and frunexian hold Orphan Drug Designations, with frunexian currently in Phase 2 development.

The company reported a cash position of $3.9 million as of September 30, 2025, and a market capitalization of $23 million as of December 11, 2025. Cadrenal Therapeutics targets pivotal protocol design and an FDA End-of-Phase-2 meeting in 2026, with pivotal study initiation planned for 2027.

Leadership includes Matthew Szot as Chief Financial Officer, Jeff Cole as Chief Operating Officer, and James Ferguson as Chief Medical Officer. The board comprises Lee Golden, John R. Murphy, Steven Zelenkofske, DO, and Glynn Wilson, PhD.